obesity diabetes new targets in heart failure management
play

Obesity & Diabetes: New targets in heart failure management - PowerPoint PPT Presentation

Obesity & Diabetes: New targets in heart failure management Rudolf A. de Boer, MD, FESC, FHFA University Medical Center Groningen Groningen, the Netherlands Novel concepts and treatments of comorbidities in Heart Failure with Preserved


  1. Obesity & Diabetes: New targets in heart failure management Rudolf A. de Boer, MD, FESC, FHFA University Medical Center Groningen Groningen, the Netherlands Novel concepts and treatments of comorbidities in Heart Failure with Preserved Ejection Fraction Sunday May 27, 12:45-14:00

  2. Faculty Disclosure Declaration of financial interests For the last 3 years and the subsequent 12 months: I I have received a research grant(s)/ in kind support A From current sponsor(s) YES NO B From any institution YES NO II I have been a speaker or participant in accredited CME/CPD A From current sponsor(s) YES NO B From any institution YES NO III I have been a consultant/strategic advisor etc A For current sponsor(s) YES NO B For any institution YES NO IV I am a holder of (a) patent/shares/stock ownerships A Related to presentation YES NO B Not related to presentation YES NO

  3. Faculty Disclosure: Rudolf A. de Boer MD PhD Declaration of non-financial interests: • University of Groningen, Groningen, the Netherlands • Professor of Cardiology, Cardiologist, Director of Experimental Cardiology • Dr. de Boer is supported by the Netherlands Heart Foundation (CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21, and CVON RED-CVD, grant 2017-11); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). • Board member, Heart Failure Association (HFA) of the ESC • Chair, study group on HFpEF of the HFA • Member ESC Advocacy committee • Chair, working group of Heart Failure of the Dutch Society of Cardiology

  4. Obesity Trends* Among U.S. Adults BRFSS, 1990, 1995, 2005 (*BMI  30, or about 30 lbs overweight for 5’4” person) 1995 1990 2005 No Data <10% 10% – 14% 15% – 19% 20% – 24% 25% –29% ≥30% University Medical Center Groningen

  5. Overlapping risk factors University Medical Center Groningen

  6. BMI and Diabetes: Predictors for new onset HFpEF • 28,820 individuals from the 4 large cohort studies, 12 years of FU • 811 new onset HFpEF (39%) • 200 new onset HFmrEF (10%) FHS/PREVEND/CVS/MESA • 1048 new onset HFrEF (51%) Bhambhani V, et al. Eur J Heart Fail. 2018; 20 :651-659 University Medical Center Groningen

  7. Current pathophysiological paradigm: Obesity and DM are important drivers of HFpEF Shah, SJ et al. Circulation. 2016; 134 :73-90 University Medical Center Groningen

  8. Treatment of obesity Neeland IJ, et al. Circulation. 2018; 137 :1391 – 1406 University Medical Center Groningen

  9. Bariatric surgery and HFpEF Rodriguez Flores M, et al. Expert Rev Cardiovasc Ther. 2017; 15 :567-579 University Medical Center Groningen

  10. Obesity-related HFpEF Speculation! Packer M. JACC: Heart Failure 2018 University Medical Center Groningen

  11. Obesity paradox Padwal R, et al. Int J Obes (Lond). 2014; 38 :1110-1114 Carbone S, et al. Mayo Clin Proc. 2017; 92 :266-279 University Medical Center Groningen

  12. Obesity: Contributor or confounder of HFpEF? Kitzman DW & Shah SJ. J Am Coll Cardiol HF. 2016; 68 :200-203 University Medical Center Groningen

  13. Obesity: substantial heterogeneity Neeland IJ, et al. Circulation. 2018; 137 :1391 – 1406 University Medical Center Groningen

  14. Carbone S, et al. Mayo Clin Proc. 2017; 92 :266-279 University Medical Center Groningen

  15. Obese-HFpEF phenotype is clinically relevant • Obese HFpEF patients (N = 99) were compared to non-obese HFpEF patients (N = 96) and control subjects free of HF (N = 71) • Characteristics of obese HFpEF patients • Increased plasma volume • More concentric LV remodeling • Greater RV dilation and more RV dysfunction • Increased epicardial fat thickness • Greater total epicardial heart volume Obokata M, Circulation. 2017; 136 : 6-19 University Medical Center Groningen

  16. Exercise capacity & hemodynamic reserve reduced in obese HFpEF patients Obokata M, Circulation. 2017; 136 : 6-19 University Medical Center Groningen

  17. HF and Fitness: Role of BMI Low Cardiorespiratory Fitness High Cardiorespiratory Fitness Lavie CJ, et al. Mayo Clin Proc. 2013; 88 :251-258 University Medical Center Groningen

  18. BMI stronger predictor for HFpEF than for HFrEF HF subtype by quartile of BMI HR for Incidence of HF subtype Men Women 4 P=<0.001 P<0.001 P<0.001 P=0.49 3 2 1 0 e n n W o m e n HFpEF HFrEF F HFpEF HFrEF H F r E o m e F M W E Savji N, et al. JACC Heart Fail. Accepted University Medical Center Groningen

  19. Obesity and Sex: Effects on NT-proBNP PREVEND study: 8,592 subjects, mean age 49 years Suthahar N, et al. Eur J Heart Fail. 2018; in press University Medical Center Groningen

  20. Summary 1 - Obesity • Important to have ‘ normal weight ’ • Once HFpEF: important to have sufficient lean mass • Losing fat mass: pharmacotherapy not useful, consider bariatric surgery when obesity is severe and intractable • We need to know much more about body weight, posture & sex differences University Medical Center Groningen

  21. Diabetes: a call for action IDF Diabetes Atlas, 2015 University Medical Center Groningen

  22. BMI and Diabetes: Strong predictors of new onset HFpEF • 28,820 individuals from the 4 large cohort studies, 12 years of FU • 811 new onset HFpEF (39%) • 200 new onset HFmrEF (10%) • 1048 new onset HFrEF (51%) Bhambhani V, et al. Eur J Heart Fail. 2018; 20 :651-659 University Medical Center Groningen

  23. HF in T2DM trials & T2DM in HF trials Seferovic P, et al. Eur J Heart Fail. 2018; 20: 853-872 University Medical Center Groningen

  24. Diabetes : Prognostic factor in prevalent HFpEF Kristensen, et al. Cardiovasc Drugs Ther. 2017; 31 :545-549 University Medical Center Groningen

  25. Current pathophysiological paradigm: Obesity and DM are important drivers of HFpEF Shah, SJ et al. Circulation. 2016; 134 :73-90 University Medical Center Groningen

  26. Pacher P, et al. Physiol Rev 2007; 87 :315-424 University Medical Center Groningen

  27. Paulus & Da Canto. J Am Coll Cardiol HF. 2018; 6 :1 – 7. University Medical Center Groningen

  28. Cardiovascular phenotype of patients with HFpEF with and without Diabetes • RELAX trial (216 stable outpatients with HF, EF > 50%) • Non-diabetic (N = 123); Diabetic (N = 93) • Diabetic patients were • Younger, more often male • More obese • Higher prevalence of hypertension, renal dysfunction, pulmonary disease & vascular disease Lindman BR, J Am Coll Cardiol. 2014; 64 : 541-9 University Medical Center Groningen

  29. End points in HFpEF patients with and without diabetes Lindman BR, J Am Coll Cardiol. 2014; 64 : 541-9 University Medical Center Groningen

  30. Treatment of T2DM in HF Seferovic P, et al. Eur J Heart Fail. 2018; 20: 853-872. University Medical Center Groningen

  31. Treatment of T2DM in HF Seferovic P, et al. Eur J Heart Fail. 2018; 20: 853-872. University Medical Center Groningen

  32. SGLT-2 trials in HFpEF Seferovic P, et al. Eur J Heart Fail. 2018; 20: 853-872. University Medical Center Groningen

  33. Recognized Expanded Biological Effects of GLP-1 Seufert & Gallwitz ; Diabetes Obes Metab. 2014 Aug;16(8):673-88. University Medical Center Groningen

  34. Meta-analysis: MACE-3 endpoint Bethel et al. Lancet Diabetes Endocrinol. 2017;6:105-113 University Medical Center Groningen

  35. Meta-analysis: All-cause mortality Bethel et al. Lancet Diabetes Endocrinol. 2017;6:105-113 University Medical Center Groningen

  36. Conclusion • Obesity and diabetes are amongst the most prevalent and dominant co-morbidities in HFpEF • We do not fully understand ‘obesity’ • No clear recommendations can be made for the treatment of T2DM, but SGLT-2 inhibitors and GLP1RA appear effective • Prospective RCTs are underway University Medical Center Groningen

  37. Acknowledgements & Collaborations Experimental Cardiology Wiek H. van Gilst Medical Genetics University of Maastricht, the Netherlands Herman H. Silljé Jan Jongbloed Leon. J. de Windt Peter van der Meer Irene van Langen Stephane Heymans Laura M.G. Meems Yvonne Hoedemaekers Wouter C. Meijers University of Amsterdam, the Netherlands University of Wageningen, the Netherlands Tim Eijgenraam J. Peter van Tintelen Henk A. Schols Navin Suthahar Free University of Amsterdam, the Netherlands Imperial College, London, UK Salva Yurista Alexander Lyon Arnold Piek Jolanda van der Velden Aad Withaar Bianca J. Brundel Carolin Gehlken University of Utrecht, the Netherlands Janny Takens Frans Rutte Marloes Schouten Pieter Doevendans Clinical Cardiology Dirk J. van Veldhuisen University of Michigan, USA Pim van der Harst Bertram Pitt Hans L. Hillege Boxford, MA, USA Adriaan A. Voors Pieter Muntendam Maarten P. van den Berg Peter van der Meer University of California, San Diego, USA Internal Medicine Alan S. Maisel Stephan J. Bakker Ron T. Gansevoort Potential Conflicts of interest: Laboratory Medicine Speaker/consultancy fees: Medcon, Novartis, Servier, Mandalmed Research grants: NWO-VIDI, Netherlands Heart Fourndation, AstraZeneca, BMS, Trevena Anneke C. Muller Kobold Minority shareholder: scPharmaceuticals Medical Biology Ruud A. Bank Harry van Goor Peter Heeringa Marten Hofker † University Medical Center Groningen

  38. University Medical Center Groningen

Recommend


More recommend